| Recruiting | Recombinant Erwinia Asparaginase and Venetoclax in Combination With Blinatumomab for the Treatment of Relapsed NCT07133997 | City of Hope Medical Center | Phase 1 |
| Not Yet Recruiting | Pomalidomide After CAR T-cell Therapy for the Treatment of Relapsed or Refractory CD19+ B-cell Leukemia or Lym NCT07532525 | University of Michigan Rogel Cancer Center | Phase 1 |
| Withdrawn | Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy NCT05936229 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Withdrawn | A Study of the Drug IMGN632 in Children With Leukemia That Has Come Back After Treatment or is Difficult to Tr NCT05320380 | Children's Oncology Group | Phase 1 / Phase 2 |
| Recruiting | Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lym NCT05418088 | Sumithira Vasu | Phase 1 |
| Terminated | Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Ly NCT05032183 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Withdrawn | Inotuzumab Ozogamicin and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory CD22+ NCT03851081 | Roswell Park Cancer Institute | Phase 1 / Phase 2 |
| Terminated | Blinatumomab Bridging Therapy for BALL NCT04556084 | Michael Burke | Phase 2 |
| Completed | Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies NCT04681105 | City of Hope Medical Center | Phase 1 |
| Unknown | Dual Target CAR-T Cells in B-cell Acute Lymphoblastic Leukemia NCT04723901 | Shenzhen University General Hospital | Phase 1 / Phase 2 |
| Terminated | CD19-Specific T Cells Post AlloSCT NCT03579888 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Recurrent or Refractory B-cell Acute Lymphobl NCT03991884 | University of Washington | Phase 1 |
| Withdrawn | Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, NCT04029038 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Recruiting | Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Re NCT03739814 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Low-Intensity Chemotherapy and Venetoclax in Treating Patients With Relapsed or Refractory B- or T-Cell Acute NCT03808610 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Terminated | ADCT-602 in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia NCT03698552 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Active Not Recruiting | Venetoclax and Vincristine in Treating Patients With Relapsed or Refractory T-cell or B-cell Acute Lymphoblast NCT03504644 | ECOG-ACRIN Cancer Research Group | Phase 1 / Phase 2 |
| Completed | Palbociclib and Dexamethasone in Treating Participants With Relapsed or Refractory B-Cell Acute Lymphoblastic NCT03472573 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Phase 1 |
| Terminated | Low-Intensity Chemotherapy and Blinatumomab in Treating Patients With Philadelphia Chromosome Negative Relapse NCT03518112 | M.D. Anderson Cancer Center | Phase 2 |
| Terminated | huJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Ac NCT03103971 | Fred Hutchinson Cancer Center | Phase 1 |
| Active Not Recruiting | Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refracto NCT02879695 | National Cancer Institute (NCI) | Phase 1 |
| Withdrawn | Safety and Efficacy of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy in R/R Acute B Lymphoblastic Le NCT04094766 | Second Affiliated Hospital of Xi'an Jiaotong University | Phase 1 |
| Recruiting | Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD2 NCT02981628 | Children's Oncology Group | Phase 2 |
| Terminated | Ruxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed or Refractory Philadel NCT02420717 | M.D. Anderson Cancer Center | Phase 2 |
| Recruiting | Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia NCT01371630 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |